← SynDRA
LINAGLIPTIN
SynDRA canonical compound SYN0007646 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | DPP4 |
|---|
| Mechanism of action | Dipeptidyl peptidase inhibitor |
|---|
| Indication | diabetes mellitus |
|---|
| Disease area | endocrinology |
|---|
All known targets
- DPP4
- CHRM1
- DPP IV
- DPP9
- FAP
- Fap
Mechanisms of action (all sources)
- Dipeptidyl peptidase inhibitor
- DPP4 inhibitor
Drug classes
- Dipeptidyl-Peptidase IV Inhibitors
- Enzyme Inhibitors
- Hormones
- Hypoglycemic Agents
- Incretins
- Protease Inhibitors
- Dipeptidyl Peptidase 4 Inhibitors
- Dipeptidyl Peptidase 4 Inhibitor
ATC classes
- A10B · BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Cross-references
Synonyms
- tradjenta
- BI-1356
- Linagliptine
- Linagliptina
- Trazenta
- BI-1356-BS
- BI-1356BS
- BI1356
- BS-1356-BS
- Linagliptin component of glyxambi
- Linagliptin component of jentadueto
- Linagliptin component of trijardy xr
- Tradjenta
- Trajenta
- Ondero
- Ondero (TN)
- (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
- 3X29ZEJ4R2
- BI 1356
- GLYXAMBI COMPONENT LINAGLIPTIN
- BI 1356 BS
- TRIJARDY XR COMPONENT LINAGLIPTIN
- linagliptine
- CHEBI:68610
- linagliptinum
- RefChem:5948
- A10BH05
- DTXCID801506661
- Linagliptin (BI-1356)
- MFCD14635356
- ione
- C25H28N8O2
- UNII-3X29ZEJ4R2
- Linaglitpin
- Linagliptin [USAN:INN:JAN]
- HSDB 8204
- Tradjenta (TN)
- Linagliptin (Standard)
Reported adverse events
- Lactic acidosis
- Hypersensitivity
- Pancreatitis
- Nasopharyngitis
- Cough
- Arthralgia
- Rhabdomyolysis
- Rash
Look up LINAGLIPTIN in the interactive SynDRA portal →